Education
About Us
Working with TipRanks
Follow Us
Ian Roy Johnson Insider Profile
4 Followers
Ian Roy Johnson, Director at Ergomed, holds 4.62M shares in Circassia Pharmaceuticals (Ticker: GB:NIOX), holds 10.00K shares in Ergomed (Ticker: GB:ERGO).
Profitable Transactions
4 out of 9 Profitable Transactions
Average Return
+12.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Ian Roy Johnson's holdings
Insider Roles
Director
Roles that Ian Roy Johnson holds in companies
Most Profitable Insider Trade
Stock:
Ergomed
(ERGO)
(ERGO)
Rating:Informative Buy
Date:Feb 14, 2020 - Feb 14, 2021
Return:+158.80%
The most profitable trade made by Ian Roy Johnson
Ian Roy Johnson's Trading History
Ergomed
Feb 14, 2020
―
Informative Buy
45.60K
£134.60K
Circassia Pharmaceuticals
Jun 26, 2025
Director
Uninformative Buy
―
£3.19M
List of latest transactions for each holding click on a transaction to see Ian Roy Johnson's performance on stock
You May Also Like
Ian Roy Johnson insider profile FAQ
What is the percentage of profitable transactions made by Ian Roy Johnson?
The percentage of profitable transactions made by Ian Roy Johnson is 44%.
What is the average return per transaction made by Ian Roy Johnson?
The average return per transaction made by Ian Roy Johnson is 12.20%.
What stocks does Ian Roy Johnson hold?
Ian Roy Johnson holds: GB:ERGO, GB:NIOX stocks.
What was Ian Roy Johnson’s latest transaction?
Ian Roy Johnson latest transaction was an Uninformative Buy of ―.
What was Ian Roy Johnson's most profitable transaction?
Ian Roy Johnson’s most profitable transaction was an Informative Buy of GB:ERGO stock on February 14, 2020. The return on the trade was 158.80%.
What is Ian Roy Johnson's role in Ergomed?
Ian Roy Johnson's role in Ergomed is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.